New York partner Richard Segal was quoted in a Law360 piece discussing the need for capital in the biotech sector and the strong appetite among private biotech companies to go public.
“Equity capital markets plummeted to earth in the first half of 2022 amid economic headwinds and geopolitical turmoil, and they are showing little sign of a quick turnaround, marking a sharp contrast from last year’s boom.”
